Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Global cues drag Indian stock markets
Tue, 12 Jul 09:30 am

Asian stock markets have opened the day on a weak note. Stock markets in South Korea (down 2%) and Japan (down 0.5%), Indonesia (down 0.8%), China (down 1.3%) and Hong Kong (down 2.1%) are trading in the red. The Indian stock markets have opened the day on a weak note as well. Stocks in the realty and technology (IT) are leading the losses.

The BSE-Sensex is trading down by 184 points (1%) and the NSE-Nifty is down by around 53 points (1%). Midcap and small cap stocks are trading in the red as well, with the BSE Midcap and BSE Small cap indices down by 0.5% and 0.3% respectively. The rupee is trading at 44.46 to the US dollar.

FMCG (Fast moving consumer goods) stocks have opened the day on a mixed note with Marico and Dabur trading in the red. However, Nestle and Colgate Palmolive are trading in the green. Reinforcing its faith in India, the world's largest consumer goods company, Procter & Gamble (P&G) has decided to invest Rs 34.5 bn in P&G Home Products. P&G Home Products is the unlisted subsidiary of the global major in India. The investment will power P&G's Project 2-3-4 that aims to double the number of Indians who use its products. P&G already has a presence in India through its listed subsidiary P&G Health & Hygiene. The subsidiary markets feminine hygiene products and Vicks. It also has a presence in the men's grooming products through its listed subsidiary, Gillette India. P&G Home Products is P&G's largest subsidiary and has an established presence in categories like laundry, hair care and skin care. P&G's investments in its subsidiaries are with an intent to reduce the gap with its biggest rival, Hindustan Unilever (HUL).

Pharma stocks have opened the day on a mixed note with Cadila and Cipla in the red while Dr Reddy's Lab and Piramal Healthcare trading in the green. Ranbaxy and Pfizer have planned an alliance with the FMCG major ITC to sell their over-the-counter (OTC) products in the rural market. Ranbaxy has products like Volini, in pain segment and Pfizer has Becosule, a multivitamin tablet which may no longer be available to the urban areas. The details of the development have not been disclosed by the companies. It is also not clear whether the OTC products would be available only with chemists or with grocery and kirana stores as well. It is reported by a leading newspaper that a pilot project is also being carried out in Uttar Pradesh.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Global cues drag Indian stock markets". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.